295 related articles for article (PubMed ID: 12150711)
21. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.
Gault VA; Kerr BD; Irwin N; Flatt PR
Biochem Pharmacol; 2008 Jun; 75(12):2325-33. PubMed ID: 18455149
[TBL] [Abstract][Full Text] [Related]
22. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo.
Gault VA; Parker JC; Harriott P; Flatt PR; O'Harte FP
J Endocrinol; 2002 Nov; 175(2):525-33. PubMed ID: 12429050
[TBL] [Abstract][Full Text] [Related]
23. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
[TBL] [Abstract][Full Text] [Related]
24. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
25. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
26. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats.
Hinke SA; Gelling RW; Pederson RA; Manhart S; Nian C; Demuth HU; McIntosh CH
Diabetes; 2002 Mar; 51(3):652-61. PubMed ID: 11872663
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
28. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
[TBL] [Abstract][Full Text] [Related]
29. Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25.
Martin CM; Gault VA; McClean S; Flatt PR; Irwin N
Biochem Pharmacol; 2012 Aug; 84(3):312-9. PubMed ID: 22561048
[TBL] [Abstract][Full Text] [Related]
30. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
[TBL] [Abstract][Full Text] [Related]
31. Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide.
Kerr BD; Flatt AJ; Flatt PR; Gault VA
Biochem Biophys Res Commun; 2011 Jan; 404(3):870-6. PubMed ID: 21184739
[TBL] [Abstract][Full Text] [Related]
32. Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide.
Gault VA; Harriott P; Flatt PR; O'Harte FP
Biosci Rep; 2002; 22(5-6):523-8. PubMed ID: 12635849
[TBL] [Abstract][Full Text] [Related]
33. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.
Gault VA; Flatt PR; O'Harte FP
Biochem Biophys Res Commun; 2003 Aug; 308(2):207-13. PubMed ID: 12901855
[TBL] [Abstract][Full Text] [Related]
34. A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents.
Tatarkiewicz K; Hargrove DM; Jodka CM; Gedulin BR; Smith PA; Hoyt JA; Lwin A; Collins L; Mamedova L; Levy OE; D'Souza L; Janssen S; Srivastava V; Ghosh SS; Parkes DG
Diabetes Obes Metab; 2014 Jan; 16(1):75-85. PubMed ID: 23859463
[TBL] [Abstract][Full Text] [Related]
35. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
[TBL] [Abstract][Full Text] [Related]
36. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Green BD; Gault VA; O'harte FP; Flatt PR
Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
[TBL] [Abstract][Full Text] [Related]
37. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
39. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).
Irwin N; Green BD; Parker JC; Gault VA; O'Harte FP; Flatt PR
Regul Pept; 2006 Jul; 135(1-2):45-53. PubMed ID: 16675042
[TBL] [Abstract][Full Text] [Related]
40. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men.
Carr RD; Larsen MO; Jelic K; Lindgren O; Vikman J; Holst JJ; Deacon CF; Ahrén B
J Clin Endocrinol Metab; 2010 Feb; 95(2):872-8. PubMed ID: 20008019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
